OperaV1, PascalFrancis, Corpus, bibRecord, 000330

Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects

Identifieur interne : 000330 ( PascalFrancis/Corpus ); précédent : 000329; suivant : 000331

Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects

Auteurs : O. Ukkola ; Y. A. Kes Niemi

Source :

European journal of clinical nutrition [ 0954-3007 ] ; 2007.

RBID : Pascal:07-0426249

Descripteurs français

Pascal (Inist)
- Diabète type 2, Polymorphisme, Association, Facteur risque, Risque, Age mûr, Homme, Nutrition.

English descriptors

KwdEn :
- Association, Human, Middle age, Nutrition, Polymorphism, Risk, Risk factor, Type 2 diabetes.

Abstract

Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n= 515) and control cohorts (n = 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio = 3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0954-3007`
A03		`1`		`@0 Eur. j. clin. nutr.`
A05				`@2 61`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects`
A11	`01`	`1`		`@1 UKKOLA (O.)`
A11	`02`	`1`		`@1 KESÄNIEMI (Y. A.)`
A14	`01`			`@1 Department of Internal Medicine and Biocenter Oulu, University of Oulu @2 Oulu @3 FIN @Z 1 aut. @Z 2 aut.`
A20				`@1 1102-1105`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18249 @5 354000149692660090`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 1/2 p.`
A47	`01`	`1`		`@0 07-0426249`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 European journal of clinical nutrition`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n= 515) and control cohorts (n = 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio = 3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None.
C02	`01`	`X`		`@0 002B22`
C02	`02`	`X`		`@0 002B21E01A`
C03	`01`	`X`	`FRE`	`@0 Diabète type 2 @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Type 2 diabetes @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Diabetes de tipo 2 @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Polymorphisme @5 02`
C03	`02`	`X`	`ENG`	`@0 Polymorphism @5 02`
C03	`02`	`X`	`SPA`	`@0 Polimorfismo @5 02`
C03	`03`	`X`	`FRE`	`@0 Association @5 03`
C03	`03`	`X`	`ENG`	`@0 Association @5 03`
C03	`03`	`X`	`SPA`	`@0 Asociación @5 03`
C03	`04`	`X`	`FRE`	`@0 Facteur risque @5 05`
C03	`04`	`X`	`ENG`	`@0 Risk factor @5 05`
C03	`04`	`X`	`SPA`	`@0 Factor riesgo @5 05`
C03	`05`	`X`	`FRE`	`@0 Risque @5 06`
C03	`05`	`X`	`ENG`	`@0 Risk @5 06`
C03	`05`	`X`	`SPA`	`@0 Riesgo @5 06`
C03	`06`	`X`	`FRE`	`@0 Age mûr @5 08`
C03	`06`	`X`	`ENG`	`@0 Middle age @5 08`
C03	`06`	`X`	`SPA`	`@0 Edad media @5 08`
C03	`07`	`X`	`FRE`	`@0 Homme @5 09`
C03	`07`	`X`	`ENG`	`@0 Human @5 09`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 09`
C03	`08`	`X`	`FRE`	`@0 Nutrition @5 11`
C03	`08`	`X`	`ENG`	`@0 Nutrition @5 11`
C03	`08`	`X`	`SPA`	`@0 Nutrición @5 11`
C07	`01`	`X`	`FRE`	`@0 Endocrinopathie @5 37`
C07	`01`	`X`	`ENG`	`@0 Endocrinopathy @5 37`
C07	`01`	`X`	`SPA`	`@0 Endocrinopatía @5 37`
C07	`02`	`X`	`FRE`	`@0 Métabolisme pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Metabolic diseases @5 38`
C07	`02`	`X`	`SPA`	`@0 Metabolismo patología @5 38`
N21				`@1 281`

Format Inist (serveur)

NO :	PASCAL 07-0426249 INIST
ET :	Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects
AU :	UKKOLA (O.); KESÄNIEMI (Y. A.)
AF :	Department of Internal Medicine and Biocenter Oulu, University of Oulu/Oulu/Finlande (1 aut., 2 aut.)
DT :	Publication en série; Niveau analytique
SO :	European journal of clinical nutrition; ISSN 0954-3007; Royaume-Uni; Da. 2007; Vol. 61; No. 9; Pp. 1102-1105; Bibl. 1/2 p.
LA :	Anglais
EA :	Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n= 515) and control cohorts (n = 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio = 3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None.
CC :	002B22; 002B21E01A
FD :	Diabète type 2; Polymorphisme; Association; Facteur risque; Risque; Age mûr; Homme; Nutrition
FG :	Endocrinopathie; Métabolisme pathologie
ED :	Type 2 diabetes; Polymorphism; Association; Risk factor; Risk; Middle age; Human; Nutrition
EG :	Endocrinopathy; Metabolic diseases
SD :	Diabetes de tipo 2; Polimorfismo; Asociación; Factor riesgo; Riesgo; Edad media; Hombre; Nutrición
LO :	INIST-18249.354000149692660090
ID :	07-0426249

Links to Exploration step

Pascal:07-0426249

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects</title>
<author><name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0426249</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0426249 INIST</idno>
<idno type="RBID">Pascal:07-0426249</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000330</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects</title>
<author><name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European journal of clinical nutrition</title>
<title level="j" type="abbreviated">Eur. j. clin. nutr.</title>
<idno type="ISSN">0954-3007</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European journal of clinical nutrition</title>
<title level="j" type="abbreviated">Eur. j. clin. nutr.</title>
<idno type="ISSN">0954-3007</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Association</term>
<term>Human</term>
<term>Middle age</term>
<term>Nutrition</term>
<term>Polymorphism</term>
<term>Risk</term>
<term>Risk factor</term>
<term>Type 2 diabetes</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Diabète type 2</term>
<term>Polymorphisme</term>
<term>Association</term>
<term>Facteur risque</term>
<term>Risque</term>
<term>Age mûr</term>
<term>Homme</term>
<term>Nutrition</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n= 515) and control cohorts (n = 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio = 3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0954-3007</s0>
</fA01>
<fA03 i2="1"><s0>Eur. j. clin. nutr.</s0>
</fA03>
<fA05><s2>61</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>UKKOLA (O.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KESÄNIEMI (Y. A.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Internal Medicine and Biocenter Oulu, University of Oulu</s1>
<s2>Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>1102-1105</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18249</s2>
<s5>354000149692660090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1/2 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0426249</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>European journal of clinical nutrition</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n= 515) and control cohorts (n = 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio = 3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B22</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B21E01A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Diabète type 2</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Type 2 diabetes</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Diabetes de tipo 2</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Polymorphisme</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Polymorphism</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Polimorfismo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Association</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Association</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Asociación</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Risque</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Risk</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Riesgo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Age mûr</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Middle age</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Edad media</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Nutrition</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Nutrition</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Nutrición</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Endocrinopathie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Endocrinopathy</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Endocrinopatía</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Métabolisme pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>281</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 07-0426249 INIST</NO>
<ET>Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects</ET>
<AU>UKKOLA (O.); KESÄNIEMI (Y. A.)</AU>
<AF>Department of Internal Medicine and Biocenter Oulu, University of Oulu/Oulu/Finlande (1 aut., 2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>European journal of clinical nutrition; ISSN 0954-3007; Royaume-Uni; Da. 2007; Vol. 61; No. 9; Pp. 1102-1105; Bibl. 1/2 p.</SO>
<LA>Anglais</LA>
<EA>Objectives: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. Design: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n= 515) and control cohorts (n = 525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. Results: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio = 3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. Conclusions: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels. Sponsorship: None.</EA>
<CC>002B22; 002B21E01A</CC>
<FD>Diabète type 2; Polymorphisme; Association; Facteur risque; Risque; Age mûr; Homme; Nutrition</FD>
<FG>Endocrinopathie; Métabolisme pathologie</FG>
<ED>Type 2 diabetes; Polymorphism; Association; Risk factor; Risk; Middle age; Human; Nutrition</ED>
<EG>Endocrinopathy; Metabolic diseases</EG>
<SD>Diabetes de tipo 2; Polimorfismo; Asociación; Factor riesgo; Riesgo; Edad media; Hombre; Nutrición</SD>
<LO>INIST-18249.354000149692660090</LO>
<ID>07-0426249</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000330 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000330 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0426249
   |texte=   Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects
}}

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Jan 4 23:09:23 2024

	Serveur d'exploration sur l'opéra
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'opéra

Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects

Leu7Pro polymorphism of PreproNPY associated with an increased risk for type II diabetes in middle-aged subjects

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri